{
  "id": 16913867,
  "title": "Heartflow Inc stock hits all-time high at 60.07 USD",
  "url": "https://urgent.news/2026/10/28/heartflow-inc-stock-hits-all-time-high-at-60-07-usd",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-28T14:53:06.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/heartflow-inc-stock-hits-alltime-high-at-6007-usd-93CH-4979925"
  },
  "original_language": "en",
  "account": "Heartflow Inc.'s stock achieved an all-time high of $60.07, signaling a significant achievement for the company. Currently trading at $59.97, the stock is just 1% shy of its 52-week peak of $59.90, boasting a robust year-to-date return of 98%. Over the past year, the stock has soared 59.3%, highlighting investor confidence and a positive market outlook. This surge demonstrates the company's solid performance and prospects for future expansion, as it garners increasing attention from market participants. InvestingPro analysis suggests the stock may be overvalued compared to its Fair Value, placing it among the most overvalued equities. For those interested in a deeper examination, comprehensive Pro Research Reports are available for HeartFlow and over 1,400 US stocks, converting intricate data into actionable intelligence. Recently, HeartFlow reported a smaller-than-anticipated loss for the second quarter of 2026, with adjusted earnings of -$0.07 per share, outpacing Wall Street's forecast of -$0.19 per share. Revenue rose 48% year-over-year to $64.1 million, fueled by robust demand for its coronary artery disease diagnostics. Stifel echoed this revenue figure, surpassing both its own projection of $56.7 million and the consensus estimate of $56.6 million. Piper Sandler boosted its price target for HeartFlow to $64, retaining an Overweight rating, citing the company's strong position in the FFRct and plaque analysis markets. Canaccord lifted its price target to $56, maintaining a Buy rating, following an expanded plaque analysis survey. Stifel adjusted its price target to $45, acknowledging the company's outperformance in the plaque and FFRct sectors. These developments underscore HeartFlow's solid clinical data and strategic market positioning.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}